Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932150 · ClinicalTrials.gov registry record · Phase 2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
A Phase 2 study of Chronic Hepatitis B, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT02932150 is a Phase 2 study of Chronic Hepatitis B that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 150 participants, below the 283-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02932150, a Phase 2 study of Chronic Hepatitis B, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAF
Study Locations (20)
Texas
- Children's Medical Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital - Main Hospital - Houston
- American Research Corporation at Texas Liver Institute - San Antonio
California
- Children's Hospital of Los Angeles - Los Angeles
- Rady Childrens Hospital - San Diego
- University of California, San Francisco (UCSF) - San Francisco
Florida
- University of Miami/Schiff Center for Liver Diseases - Miami
- AdventHealth Medical Group - Orlando
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Indiana
- Indiana University School of Medicine - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-11 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02932150
The ClinicalTrials.gov registry entry for NCT02932150 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (47% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02932150 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02932150 about?
NCT02932150 is a clinical study titled "Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection". The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
What is the current status of trial NCT02932150?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2016-11. Estimated completion is 2029-10.
What conditions does trial NCT02932150 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
What interventions are being tested in trial NCT02932150?
The interventions under investigation include: Placebo (DRUG), TAF (DRUG).
Who is sponsoring clinical trial NCT02932150?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02932150 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
-
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
COMPLETED · Phase 2
-
Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment
COMPLETED · Phase 2
-
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
COMPLETED · Phase 2
-
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.